Folate Receptor Alpha Autoantibodies in Early Pregnancy: First-Trimester Reference Intervals and Proposed Clinical Thresholds
Methods and Protocols · 25.05.2026 · 9 (3) · 79
DOI: 10.3390/mps9030079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Methods and Protocols, online erschienen am 25.05.2026. Verfasst von Claudio Giorlandino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Prenatal Diagnosis, Fetal-Maternal Medical Centre, Altamedica, Viale Liegi 45, 00198 Rome, Italy. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Maternal folate receptor alpha autoantibodies (FRAA) have been associated with impaired placental folate transport, fetal cerebral folate deficiency (CFD) and neurodevelopmental risks including autism spectrum disorder (ASD); however, first-trimester-specific reference intervals remain undefined. This prospective single-center study of 534 healthy pregnant women at 10 + 0 to 15 + 6 weeks’ gestation (week 10 n = 26; week 11 n = 155; week 12 n = 203; week 13 n = 105; week 14 n = 39; week 15 n = 6) used a CE-IVDR FRAA ELISA, following CLSI EP28-A3c and IFCC C-RIDL protocols, to establish week-specific percentiles (P5, P50, P95, P99) via non-parametric estimation and log-smoothed regression with a 1-week rolling window. An internal-consistency ROC analysis was performed against the within-dataset ≥P99 designation and is therefore not interpretable as discrimination against an independent clinical outcome. Median FRAA declined from 29 ng/mL (week 10) to 25 ng/mL (week 14), with provisional clinically actionable thresholds of P95 ≈ 120 ng/mL and P99 ≈ 150 ng/mL. These data provide the first first-trimester normative percentile curves for maternal FRAA and may support prioritizing FRAA assessment before 15 weeks (onset of accelerated transplacental IgG transfer). Given the cross-sectional, single-center design, the small samples at weeks 14–15, and the absence of long-term neurodevelopmental outcome data, the proposed thresholds and any downstream clinical implications, including folinic acid intervention and ASD risk mitigation, should be considered hypothesis-generating and require external and longitudinal validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Prenatal Diagnosis, Fetal-Maternal Medical Centre, Altamedica, Viale Liegi 45, 00198 Rome, Italy.
- Department of Clinical Biochemistry and Laboratory Medicine, Altamedica, Viale Liegi 45, 00198 Rome, Italy.
- Human Genetics Laboratory, Altamedica, Viale Liegi 45, 00198 Rome, Italy.
ORCID-Profile: Claudio Giorlandino, Katia Margiotti, Maria Luisa Mastrandrea, Laura D'Emidio, Alvaro Mesoraca
Zitieren
APA
Giorlandino, C., Cupellaro, M., Margiotti, K., Giorlandino, F., Pignataro, F., Mastrandrea, M. L., Raffio, R., D'Emidio, L., Mesoraca, A., & Milite, V. (2026). Folate Receptor Alpha Autoantibodies in Early Pregnancy: First-Trimester Reference Intervals and Proposed Clinical Thresholds. Methods and Protocols, 9(3), 79. https://doi.org/10.3390/mps9030079
Vancouver
Giorlandino C, Cupellaro M, Margiotti K, Giorlandino F, Pignataro F, Mastrandrea ML, et al. Folate Receptor Alpha Autoantibodies in Early Pregnancy: First-Trimester Reference Intervals and Proposed Clinical Thresholds. Methods and Protocols. 2026;9(3):79. doi:10.3390/mps9030079
BibTeX
@article{Giorlandino2026,
author = {Giorlandino, Claudio and Cupellaro, Marina and Margiotti, Katia and Giorlandino, Francesca and Pignataro, Francesco and Mastrandrea, Maria Luisa and Raffio, Raffaella and D'Emidio, Laura and Mesoraca, Alvaro and Milite, Vincenzo},
title = {Folate Receptor Alpha Autoantibodies in Early Pregnancy: First-Trimester Reference Intervals and Proposed Clinical Thresholds},
journal = {Methods and Protocols},
year = {2026},
volume = {9},
number = {3},
pages = {79},
doi = {10.3390/mps9030079}
}
EUVIMED